Fig. 1
Comparison of plasma immune checkpoints between subjects who spontaneously cleared HCV versus the control group: A All individuals, B Male individuals, C Female individuals. Statistics: Data were calculated by Generalized Linear Models (GLM) with a gamma distribution (log-link) adjusted by those clinical variables selected following a stepwise method from age, sex, IFN-λ4 genotype (rs12979860), and aspartate transaminase (AST) for A), and by sex, IFN-λ4 genotype (rs12979860), and aspartate transaminase (AST) for B) and C), (see Results Section). The q-values represent p-values corrected for multiple testing using the False Discovery Rate (FDR). Significant differences are shown in bold. Abbreviations: AMR, arithmetic mean ratio; aAMR, adjusted AMR; 95%CI, 95% of confidence interval; q, corrected level of significance; BTLA, B and T lymphocyte attenuator; CD, cluster of differentiation; GITR, glucocorticoid-induced TNFR-related; HVEM, herpesvirus entry mediator; IDO, indoleamine 2,3-dioxygenase; LAG-3, lymphocyte activation gene-3; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PD-L2, programmed death-ligand 2; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; MICA, MHC class I chain-related gene A; MICB, MHC class I chain-related gene B; NT5E, ecto-5′-nucleotidase; PVR, poliovirus receptor; Siglec, sialic acid-binding immunoglobulin-type lectin; ULBP, human ligand for binding protein